Literature DB >> 19433553

Pyrazolopyrimidinediones are selective agents for Helicobacter pylori that suppress growth through inhibition of glutamate racemase (MurI).

B L M de Jonge1, A Kutschke, M Uria-Nickelsen, H D Kamp, S D Mills.   

Abstract

Pyrazolopyrimidinediones are a novel series of compounds that inhibit growth of Helicobacter pylori specifically. Using a variety of methods, advanced analogues were shown to suppress the growth of H. pylori through the inhibition of glutamate racemase, an essential enzyme in peptidoglycan biosynthesis. The high degree of selectivity of the series for H. pylori makes these compounds attractive candidates for novel H. pylori-selective therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19433553      PMCID: PMC2715633          DOI: 10.1128/AAC.00226-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Regulated gene expression in Staphylococcus aureus for identifying conditional lethal phenotypes and antibiotic mode of action.

Authors:  L Zhang; F Fan; L M Palmer; M A Lonetto; C Petit; L L Voelker; A St John; B Bankosky; M Rosenberg; D McDevitt
Journal:  Gene       Date:  2000-09-19       Impact factor: 3.688

2.  Morphologic conversion of Helicobacter pylori from bacillary to coccoid form.

Authors:  M Sörberg; M Nilsson; H Hanberger; L E Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

3.  Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor.

Authors:  D Z Chen; D V Patel; C J Hackbarth; W Wang; G Dreyer; D C Young; P S Margolis; C Wu; Z J Ni; J Trias; R J White; Z Yuan
Journal:  Biochemistry       Date:  2000-02-15       Impact factor: 3.162

4.  Structural characterization of peptidoglycan muropeptides by matrix-assisted laser desorption ionization mass spectrometry and postsource decay analysis.

Authors:  N Xu; Z H Huang; B L de Jonge; D A Gage
Journal:  Anal Biochem       Date:  1997-05-15       Impact factor: 3.365

5.  Helicobacter pylori infection and the development of gastric cancer.

Authors:  N Uemura; S Okamoto; S Yamamoto; N Matsumura; S Yamaguchi; M Yamakido; K Taniyama; N Sasaki; R J Schlemper
Journal:  N Engl J Med       Date:  2001-09-13       Impact factor: 91.245

6.  Compound efflux in Helicobacter pylori.

Authors:  Amy Kutschke; Boudewijn L M de Jonge
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  Exploitation of structural and regulatory diversity in glutamate racemases.

Authors:  Tomas Lundqvist; Stewart L Fisher; Gunther Kern; Rutger H A Folmer; Yafeng Xue; D Trevor Newton; Thomas A Keating; Richard A Alm; Boudewijn L M de Jonge
Journal:  Nature       Date:  2007-06-14       Impact factor: 49.962

8.  Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori.

Authors:  R A Alm; L S Ling; D T Moir; B L King; E D Brown; P C Doig; D R Smith; B Noonan; B C Guild; B L deJonge; G Carmel; P J Tummino; A Caruso; M Uria-Nickelsen; D M Mills; C Ives; R Gibson; D Merberg; S D Mills; Q Jiang; D E Taylor; G F Vovis; T J Trust
Journal:  Nature       Date:  1999-01-14       Impact factor: 49.962

9.  A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.

Authors:  Ellen Z Baum; Steven M Crespo-Carbone; Alexandra Klinger; Barbara D Foleno; Ignatius Turchi; Mark Macielag; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

10.  Bactericidal and morphological effects of amoxicillin on Helicobacter pylori.

Authors:  V Berry; K Jennings; G Woodnutt
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  14 in total

Review 1.  Nontraditional therapies to treat Helicobacter pylori infection.

Authors:  Morris O Makobongo; Jeremy J Gilbreath; D Scott Merrell
Journal:  J Microbiol       Date:  2014-03-29       Impact factor: 3.422

2.  Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy.

Authors:  Boudewijn L M de Jonge; Amy Kutschke; Joseph V Newman; Michael T Rooney; Wei Yang; Christer Cederberg
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

Review 3.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  D-fining DarR: a LysR-type transcriptional regulator that responds to D-aspartate.

Authors:  Mark J Mandel
Journal:  J Bacteriol       Date:  2018-03-19       Impact factor: 3.490

5.  Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents.

Authors:  Ann E Eakin; Oluyinka Green; Neil Hales; Grant K Walkup; Shanta Bist; Alok Singh; George Mullen; Joanna Bryant; Kevin Embrey; Ning Gao; Alex Breeze; Dave Timms; Beth Andrews; Maria Uria-Nickelsen; Julie Demeritt; James T Loch; Ken Hull; April Blodgett; Ruth N Illingworth; Bryan Prince; P Ann Boriack-Sjodin; Sheila Hauck; Lawrence J MacPherson; Haihong Ni; Brian Sherer
Journal:  Antimicrob Agents Chemother       Date:  2011-12-19       Impact factor: 5.191

6.  Strategies for the Synthesis of the Halenaquinol and Xestoquinol Families of Natural Products.

Authors:  Gregg M Schwarzwalder; Christopher D Vanderwal
Journal:  European J Org Chem       Date:  2017-02-16

7.  Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Authors:  Gregory S Basarab; Gunther H Kern; John McNulty; John P Mueller; Kenneth Lawrence; Karthick Vishwanathan; Richard A Alm; Kevin Barvian; Peter Doig; Vincent Galullo; Humphrey Gardner; Madhusudhan Gowravaram; Michael Huband; Amy Kimzey; Marshall Morningstar; Amy Kutschke; Sushmita D Lahiri; Manos Perros; Renu Singh; Virna J A Schuck; Ruben Tommasi; Grant Walkup; Joseph V Newman
Journal:  Sci Rep       Date:  2015-07-14       Impact factor: 4.379

8.  Glutamate Racemase Mutants of Bacillus anthracis.

Authors:  So-Young Oh; Stefan G Richter; Dominique M Missiakas; Olaf Schneewind
Journal:  J Bacteriol       Date:  2015-03-16       Impact factor: 3.490

9.  A Synthesis of Exiguaquinol Dessulfate.

Authors:  Gregg M Schwarzwalder; David R Scott; Christopher D Vanderwal
Journal:  Chemistry       Date:  2016-10-26       Impact factor: 5.236

10.  Competing Substrates for the Bifunctional Diaminopimelic Acid Epimerase/Glutamate Racemase Modulate Peptidoglycan Synthesis in Chlamydia trachomatis.

Authors:  Raghuveer Singh; Jessica A Slade; Mary Brockett; Daniel Mendez; George W Liechti; Anthony T Maurelli
Journal:  Infect Immun       Date:  2020-12-15       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.